GLT-1的阳性全调节器降低了小鼠的甲基胺超位移,敏感化和有条件的位置偏好
Prateek Mokkarala1, Sonita Wiah1, Ellen M Unterwald2
1Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Neuroscience research
|February 2, 2025
概括
NA-014,一种谷氨酸转运器亚型1 (GLT-1) 阳性全调节器,减少了小鼠的甲基胺诱导的行为. 这表明GLT-1 PAM可能是刺激剂使用障碍的潜在治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 成研究 研究成研究
背景情况:
- 滥用甲基胺 (METH) 是一个重要的公共卫生问题.
- 增强的谷氨酸传递与METH的精神刺激作用有关.
- 向谷氨酸转运体提供了一个潜在的治疗途径.
研究的目的:
- 为了研究NA-014的疗效,GLT-1阳性全调节器 (PAM),在减少METH诱导的行为影响.
- 为了确定NA-014是否可以减轻METH诱导的超运动,行为敏感化和有条件的位置偏好 (CPP).
主要方法:
- 雄性小鼠接受了NA-014 (60 mg/kg) 与METH.结合使用.
- 评估了运动运动活动,行为敏感化和METH CPP.
- 空间记忆被评估,以排除一般认知障碍.
主要成果:
- NA-014 显著减少了METH引起的急性行走.
- NA-014减弱了对METH重复暴露的行为敏感性的发展.
- 调节后的NA-014给药降低了METH CPP表达,但在调节期间没有.
- NA-014并没有影响空间记忆.
结论:
- 像NA-014一样的GLT-1 PAMs显示出缓解METH相关行为结果的潜力.
- 针对GLT-1可能为管理兴奋剂使用障碍提供一种新的治疗策略.
- 对GLT-1PAM的进一步研究对于成治疗的发展是有必要的.
相关概念视频
Glucagon-like Receptor Agonists
292
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
292
Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
243
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
243
Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K


